Latest Financial Results News

DTI Group Ltd reported an 11% revenue increase and secured a $4 million Adelaide Metro contract, alongside a $2.69 million capital raise to fuel growth. The company also deepened global partnerships and enhanced its technology platform during FY25.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Vinyl Group Ltd reports a striking 190% revenue increase in FY25, driven by acquisitions and organic growth, while preparing for its first EBITDA positive quarter by December 2025.

Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Pengana Private Equity Trust reported a robust FY25 with a 7.6% NAV increase and a strong net profit of $50 million, underpinned by a diversified global private equity portfolio and a strategic buyback program.

Vmoto Limited reported a 10.8% revenue decline to $20.8 million in H1 2025 but reduced its net loss slightly to $3 million, buoyed by resilient international sales and a strategic partnership with Uber to electrify delivery fleets across Europe.

Platformo Ltd reported a 38% revenue increase driven by its Malaysian software arm Biztrak, alongside a modest improvement in its half-year loss. The company continues to navigate regulatory shifts and product enhancements in a competitive software market.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Steamships Trading Company Limited reported a modest 1.7% dip in half-year profit despite a 6.7% rise in revenue, driven by strong divisional performances and significant property gains. The company’s increased capital investment and cautious outlook highlight ongoing challenges and opportunities in Papua New Guinea’s economic landscape.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.